Abstract：
OBJECTIVE: To evaluate the impact of CDK4/6 inhibitors on erythrocyte mean corpuscular volume (MCV) change and its possible correlation with progression-free survival (PFS) and overall survival (OS).
METHODS: Observational study. Place and Duration of the Study: Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkiye, between January 2020 and 2023.
METHODS: The data of 74 patients with HR (+) HER2 (-) metastatic breast cancer were analysed retrospectively. MCV and other complete blood count metrics were noted before and after the treatment. The first post-treatment evaluation was performed at three months. The median ΔMCV values at the third month after treatment-baseline were calculated.
RESULTS: The patients were all females, with a median age of 55 years (between 35 and 80). Prior to the therapy, the baseline median MCV level was 90.4 (min-max: 77.3-113.2). After three months, the median MCV level was 95 (min-max: 84.3-115.3). Moreover, 7.15 was the median ΔMCV level. Regarding PFS (16.53 vs. 15.26 months) (p = 0.13) and OS (21.46 vs. 17.83 months) (p = 0.08), there was no statistically significant difference seen between the group with ΔMCV ≥7.15 and the group with ΔMCV <7.15.
CONCLUSIONS: CDK4/6 inhibitors led to an increase in MCV but there was no significant difference between PFS or OS and the increase in MCV. To figure out whether the rise in MCV represents a prognostic or predictive marker, further research is required.
BACKGROUND: Breast cancer, CDK4/6 inhibitors, Mean corpuscular volume, Prognosis.
METHODS: Observational study. Place and Duration of the Study: Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkiye, between January 2020 and 2023.
METHODS: The data of 74 patients with HR (+) HER2 (-) metastatic breast cancer were analysed retrospectively. MCV and other complete blood count metrics were noted before and after the treatment. The first post-treatment evaluation was performed at three months. The median ΔMCV values at the third month after treatment-baseline were calculated.
RESULTS: The patients were all females, with a median age of 55 years (between 35 and 80). Prior to the therapy, the baseline median MCV level was 90.4 (min-max: 77.3-113.2). After three months, the median MCV level was 95 (min-max: 84.3-115.3). Moreover, 7.15 was the median ΔMCV level. Regarding PFS (16.53 vs. 15.26 months) (p = 0.13) and OS (21.46 vs. 17.83 months) (p = 0.08), there was no statistically significant difference seen between the group with ΔMCV ≥7.15 and the group with ΔMCV <7.15.
CONCLUSIONS: CDK4/6 inhibitors led to an increase in MCV but there was no significant difference between PFS or OS and the increase in MCV. To figure out whether the rise in MCV represents a prognostic or predictive marker, further research is required.
BACKGROUND: Breast cancer, CDK4/6 inhibitors, Mean corpuscular volume, Prognosis.
摘要：
目的：评价CDK4/6抑制剂对红细胞平均红细胞体积(MCV)变化的影响及其与无进展生存期(PFS)和总生存期(OS)的可能相关性。
方法：观察性研究。研究的地点和持续时间：内科肿瘤科，KahramanmarasNecipFazil市医院，Kahramanmaras,Turkiye,2020年1月至2023年。
方法：回顾性分析74例HR(+)HER2(-)转移性乳腺癌患者的临床资料。在治疗前后记录MCV和其他全血细胞计数指标。在三个月时进行第一次治疗后评估。计算治疗基线后第三个月的中值ΔMCV值。
结果：患者均为女性，年龄中位数为55岁（35至80岁）。在治疗之前,基线中位MCV水平为90.4(min-max:77.3~113.2).三个月后,MCV中位数为95(min-max:84.3~115.3).此外，7.15是中值ΔMCV水平。关于PFS（16.53vs.15.26个月）（p=0.13）和OS（21.46与17.83个月)(p=0.08)，ΔMCV≥7.15组和ΔMCV<7.15组之间无统计学差异。
结论：CDK4/6抑制剂导致MCV增加，但PFS或OS与MCV增加无显著差异。为了弄清楚MCV的上升是否代表预后或预测指标，需要进一步的研究。
背景：乳腺癌，CDK4/6抑制剂，平均红细胞体积,预后。
方法：观察性研究。研究的地点和持续时间：内科肿瘤科，KahramanmarasNecipFazil市医院，Kahramanmaras,Turkiye,2020年1月至2023年。
方法：回顾性分析74例HR(+)HER2(-)转移性乳腺癌患者的临床资料。在治疗前后记录MCV和其他全血细胞计数指标。在三个月时进行第一次治疗后评估。计算治疗基线后第三个月的中值ΔMCV值。
结果：患者均为女性，年龄中位数为55岁（35至80岁）。在治疗之前,基线中位MCV水平为90.4(min-max:77.3~113.2).三个月后,MCV中位数为95(min-max:84.3~115.3).此外，7.15是中值ΔMCV水平。关于PFS（16.53vs.15.26个月）（p=0.13）和OS（21.46与17.83个月)(p=0.08)，ΔMCV≥7.15组和ΔMCV<7.15组之间无统计学差异。
结论：CDK4/6抑制剂导致MCV增加，但PFS或OS与MCV增加无显著差异。为了弄清楚MCV的上升是否代表预后或预测指标，需要进一步的研究。
背景：乳腺癌，CDK4/6抑制剂，平均红细胞体积,预后。
